Gilead Sciences | Omløpsmidler



Current Assets Endring Dato
AbbVie USD 25.58B 2.2B 2024-12
Agios Pharmaceuticals USD 965.6M 108.59M 2024-12
ALKERMES USD 1.42B 167.74M 2024-12
Alnylam Pharmaceuticals USD 3.3B 60.14M 2024-12
Amgen USD 29.03B 2.26B 2024-12
Biogen USD 7.46B 626.3M 2024-12
BioMarin Pharmaceutical USD 3.23B 175.84M 2024-12
Bristol-Myers Squibb USD 29.78B 1.7B 2024-12
Eli Lilly USD 32.74B 1.32B 2024-12
Gilead Sciences USD 19.17B 4.39B 2024-12
GlaxoSmithKline GBP 17B 301M 2024-12
Glaxosmithkline GBP 17B 301M 2024-12
Incyte USD 3.24B 430.32M 2024-12
J&J USD 55.89B 2.64B 2024-12
Merck USD 38.78B 1.58B 2024-12
Moderna USD 8.1B 1.57B 2024-12
Neurocrine Biosciences USD 1.72B 151.9M 2024-12
Novartis USD 29.7B 1.56B 2024-12
Pfizer USD 50.36B 7.14B 2024-12
PTC Therapeutics USD 1.37B 83.98M 2024-12
Regeneron Pharmaceuticals USD 27.21B 7.88B 2024-12
Sanofi 30.08B 589M 2024-06
Sarepta Therapeutics USD 3.07B 388.09M 2024-12
United Therapeutics USD 3.87B 126.5M 2024-12
Vertex Pharmaceuticals USD 9.6B 207.7M 2024-12



Gilead Sciences Omløpsmidler - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - Mar 2025.